~~<i id='6B6F8F3C93'><strike id='6B6F8F3C93'><tt id='6B6F8F3C93'><pre id='6B6F8F3C93'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：entertainment 2025-08-26 23:44:50 - browse：2521

An FDA sign — health policy coverage from STAT — Sarah Silbiger/Getty Images

WASHINGTON — There’s about to be a new acronym in town.

The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

That overhaul includes a new name: Meet the Office of Inspections and Investigations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA approves Eli Lilly ulcerative colitis treatment Omvoh

focus

knowledge

hotspot

leisure time

hotspot

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

WSS

Readout Newsletter: New research from Sanofi, Regeneron, etc.

STAT Readout Newsletter: Biotech news today

Meta's Zuckerberg and Chan on track to put $50 billion into science

STAT Summit: Meghan O’Rourke on making chronic illness visible

How AI can help patients find reliable information about doctors

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

hotspot

Wikipedia

focus

Psychedelics group wrestles with new pharma identity

ADCs take center stage as promising cancer treatments

Cancer drug shortages should be causing more outrage

Readout Newsletter: XBI biotech index, Akero Therapeutics

FDA approval of Sarepta Duchenne genetic therapy gives me hope

J&J lung cancer data amount to new salvo against AstraZeneca

Supreme Court strikes down use of affirmative action

Readout Newsletter: XBI biotech index, Akero Therapeutics

Alkermes shareholders re

Health tech investors get more selective as pandemic boom fades

knowledge

Diversifying clinical trials isn't enough to close racial gaps: study

Senate panel to vote on hospitals, PBMs, prisoner care

CDC recommends rationing of RSV shot due to shortages

The problems with dementia villages

The pink breast cancer awareness ribbon needs a redesign

Diversifying clinical trials isn't enough to close racial gaps: study

hotspot

leisure time

leisure time

hotspot